ArticleNPJ vaccines2022
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.
Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Risk of Nipah Virus Seroprevalence in Healthcare Workers: A Systematic Review with Meta-Analysis.Viruses · 2025Pooled it
- Development of a novel hybrid alphavirus-Nipah virus pseudovirion for rapid quantification of vaccine-induced neutralization antibodies.Emerging microbes & infections · 2026Article
- Nipah virus in the era of global connectivity: molecular evolution, transmission risk, and preparedness strategies.Virus genes · 2026Review
- Review
- Progression of nipah virus infection in the African green monkey: Role of macrophages and dendritic cells in early virus spread.iScience · 2026Article
- Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response.Vaccines · 2026Article
- Nipah Virus Encephalitis: Pathogenetic Aspects and Current Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2026Review
- An Evolutionary Distinct Nipah Virus N-Glycosylation Site Provides Stability for Receptor Engagement.Molecular & cellular proteomics : MCP · 2026Article
- A risk-gate mechanistic-ecological framework for assessing emergence potential of henipa-related viruses.Frontiers in microbiology · 2026Article
- Hendra virus: research progress on a bat-borne threat lurking at the human-animal interface.Frontiers in veterinary science · 2026Review
- Purification and immunogenicity of Nipah virus-like particles from insect cells.BMC biotechnology · 2025Article
- Indirect ELISAs Based on Nipah and Langya Virus Proteins for Detecting Antibodies in Animals.Infectious microbes & diseases · 2025Article
- Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.NPJ vaccines · 2025Article
- Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development.European journal of microbiology & immunology · 2025Review
- Review
- Establishing an immune correlate of protection for Nipah virus in nonhuman primates.NPJ vaccines · 2024Article
- Review
- A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.The Journal of infectious diseases · 2024Article
- A three-way interface of the Nipah virus phosphoprotein X-domain coordinates polymerase movement along the viral genome.Journal of virology · 2024Article
- Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.NPJ vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
Nipah virus (NiV) is a highly pathogenic and re-emerging virus, which causes sporadic but severe infections in humans. Currently, no vaccines against NiV have been approved. We previously showed that ChAdOx1 NiV provides full protection against a lethal challenge with NiV Bangladesh (NiV-B) in hamsters. Here, we investigated the efficacy of ChAdOx1 NiV in the lethal African green monkey (AGM) NiV challenge model. AGMs were vaccinated either 4 weeks before challenge (prime vaccination), or 8 and 4 weeks before challenge with ChAdOx1 NiV (prime-boost vaccination). A robust humoral and cellular response was detected starting 14 days post-initial vaccination. Upon challenge, control animals displayed a variety of signs and had to be euthanized between 5 and 7 days post inoculation. In contrast, vaccinated animals showed no signs of disease, and we were unable to detect infectious virus in tissues and all but one swab. No to limited antibodies against fusion protein or nucleoprotein antigen could be detected 42 days post challenge, suggesting that vaccination induced a very robust protective immune response preventing extensive virus replication.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.